Bioretec Q4'25: Kaupallistamisen perusteet käynnissä

Bioretec has been rebuilding its commercial foundation during 2025 and is seeking to restore damaged investor confidence. To finance its growth strategy, the company announced it is considering a 15 MEUR share issue. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.Topics:00:00 Introduction00:15 Bioretec’s year 202500:45 Main reasons for stalled growth02:21 The commercial progress of RemeOs03:26 Situation in China04:30 Chances in go-to-market strategy05:22 Most important things to achieve in the US this year06:40 Outlook for broadening the portfolio and expanding indications07:47 Situation in Europe08:51 Finnish hospitals09:28 Partnership possibilities10:38 KPI reporting12:59 Plans regarding funding